Patients with lung adenocarcinoma patients and ICC harboring EHBP1 or KIF5B or CAV1-MET fusions have achieved responses to crizotinib in previous case reports6,9,10 (Figure 2). The gene discussed is MET; the disease is lung adenocarcinoma.